SEC Form 4 · accession 0001140361-16-056897
BIOMARIN PHARMACEUTICAL INC · BMRN
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Jeffrey Robert Ajer
Officer — SVP, Chief Commercial Officer
Period of report
Mar 3, 2016
Accepted (ET)
Mar 7, 2016 · 8:45 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001048477
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Mar 3, 2016 | F | 2,395 | $89.57 | D | 48,137 | D | |
| Common StockF1,F2 | Mar 4, 2016 | S | 1,255 | $88.4225 | D | 46,882 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1Trade made pursuant to a 10b5-1 plan executed on May 11, 2015
- F2The price in column 4 is the weighted average price. The price actually received ranged from $87.27 to $89.32. The reporting person shall provide to the issuer, and security holder of the issuer, or the SEC staff upon request, information regarding the number of shares sold at each price within the range.